Why the study?
Does ticagrelor pretreatment reduce the composite of all-cause mortality, MI, or stent thrombosis in patients with STEMI undergoing primary PCI?
Does ticagrelor pretreatment reduce the composite of all-cause mortality, MI, or stent thrombosis in patients with STEMI undergoing primary PCI?
Ticagrelor pretreatment does not improve 30-day clinical outcomes compared to administration in the catheterization laboratory in STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
Ticagrelor pretreatment was not associated with better outcomes in STEMI primary PCI; leaves open the need for randomized confirmation of optimal timing.
BACKGROUND: The effects of ticagrelor pretreatment in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI) is debated. This study investigated the effects of ticagrelor pretreatment on clinical outcomes in this patient group. METHODS AND RESULTS: .80) with ticagrelor pretreatment. Three different statistical models were used to correct for baseline differences. No difference in the composite end point, mortality, MI, or stent thrombosis was seen between the 2 groups after statistical adjustment. No increase in in-hospital major bleeding rate was observed with ticagrelor pretreatment. CONCLUSIONS: Ticagrelor pretreatment versus ticagrelor given in the catheterization laboratory in patients with ST-segment-elevation myocardial infarction undergoing primary PCI did not improve the composite end point of all-cause mortality or MI or stent thrombosis or its individual components at 30 days.
No takes yet. Share an insight, caveat, or question.
Koul et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: